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Biomarkers for Assessing Human Female
Reproductive Health, An Interdisciplinary
Approach
Bill L. Lasley and James W. Overstreet
Institute of Toxicology and Environmental Health, University of
California, Davis, California
Identification of environmental hazards to reproductive health and characterization of the adverse
outcomes necessitate a multidisciplinary approach. Epidemiologic studies are required for the
identification of adverse health effects in human populations and then to confirm that specific
exposures are responsible. Clinical studies are required to develop assays for reproductive
biomarkers and to validate these assays prior to their application in the field. Assays for field use
must be formatted and streamlined for large-scale applications and, whenever possible,
computer algorithms should be developed to interpret biomarker data. Appropriate animal models
must be identified, biomarker assays validated for that model, and animal experiments conducted
to identify the mode of action and target organ of a putative reproductive toxicant. Finally, in vitro
studies at the level of the cell and cell organelle are essential for mechanisms of toxicity to be
clearly identified and understood. In this article we describe the interdisciplinary approach that we
have developed for study of the effects of environmental agents on female reproductive
functions. This effort requires specific skills of toxicologists, epidemiologists, physicians,
biochemists, and physiologists. Environ Health Perspect 106(Suppl 41:955-960 (1998).
http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-4/955-9601asley/abstract.html
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Introduction
The identification of environmental agents
that have adverse effects on reproductive
health is particularly challenging. As much
as 37% of all unexplained infertility in the
United States is thought to be caused by
environmental factors (1), but few human
reproductive toxicants have been clearly
identified and the mechanisms of chemical
toxicity to reproductive tract cells are not
well defined. Unlike other aspects of
human health, disturbances of reproduction
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are likely to go unrecognized or unreported.
For example, only limited assessments of
reproductive health are possible in over
50% of women in the United States
because of elective or age-related infertility.
Infertility may be periodic and it may be a
relative effect rather than an absolute condi-
tion. Couples who succeed in conception
after many years of attempting pregnancy
or have a smaller family than they desire are
afflicted with infertility, even though they
may not recognize the condition. Many
men and women do not think of infertility
as a disease and may not seek medical
advice if reproductive failure is not accom-
panied by any physical symptoms. The
incidence of reproductive disease in lower
socioeconomic groups may be dispropor-
tionately underreported because of the lim-
ited access that these individuals have to
elective medical care. Whether or not there
is any immediate discomfort or long-term
concern associated with reproductive dis-
ease, for women, in particular, the sequellae
can be devastating, and may involve irre-
versible effects on the skeletal, cardiovascu-
lar, and central nervous systems. Thus,
infertility can be regarded as a silent and
well-tolerated disease that is underreported
and sometimes misdiagnosed. Contem-
porary methods for diagnosing infertility rely
heavily on advanced, dinic-based technology
and do not lend themselves to application in
population-based studies. Surveillance of
human populations for the incidence of
reproductive disease requires the develop-
ment of practical and sensitive biomarkers
that can be used by epidemiologists in place
of the labor-intensive and costly methods
that are used for dinical evaluations.
Even when environmentally induced
reproductive disease has been documented
in a human population and one or more
toxicants is suspected of being responsible,
it is still a challenging task to identify the
cellular target(s) of toxicity and the mecha-
nism(s) of toxic action. This information
cannot be obtained by experimentation
with human subjects. Many aspects of
reproductive biology are so specific to pri-
mate species that only a nonhuman primate
model may be suitable as a surrogate for
humans in experiments that identify the tar-
get of a reproductive toxicant. Nonhuman
primates are very expensive and their supply
is limited. Nevertheless, results from whole-
animal studies are usually required to select
and design in vitro experiments that use
more widely available cells from humans or
other animals.
The basic requirements for compre-
hensive evaluation of an environmental
hazard to human female reproduction are
similar, regardless of the source of toxicity.
In this chapter, we outline the steps and
processes that we have developed to
approach such problems. This effort
involves an interdisciplinary team that
includes epidemiologists, clinical investiga-
tors, biochemists, toxicologists, and com-
parative physiologists. This article is not
intended as a comprehensive review of con-
temporary methodology for population-
based studies of female reproductive health.
For this information, the reader is referred
to specific state-of-the-art reviews (2,3).
Overview
Efforts to characterize the adverse repro-
ductive health effects of an environmental
exposure can be divided into three areas
which we conceptualize as cycles of activi-
ties (Figure 1). These activities encompass
human field studies, whole-animal toxi-
cology studies, and in vitro mechanistic
studies. One or all of these activities may
be appropriate to accomplish the objective,
depending on specific circumstances. For
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Figure 1. A schematic of the overall concept to illustrate the areas of activities for the interdisciplinary approach
to the identification and characterization of an environmental hazard. The activities start and end with the first
cycle, human studies, where an adverse health effect is perceived and documented.
example, the information which might be
gained from one cycle of activity (e.g., the
target of toxicity or the mechanism of
action) may already be known.
The first cycle of activity, which we will
refer to as human studies (Figure 1), is
composed of a logical series of research
steps that are driven by the suspicion or
recognition of an adverse reproductive out-
come in an exposed human population.
The identification of the population at risk
and the possible sources of exposure may be
activities of the epidemiologist members of
the interdisciplinary research team, or this
information may be developed by others.
The activities that follow involve a collabo-
rative effort by epidemiologists, endocrin-
ologists, and clinicians to develop and
validate a biomarker or set of biomarkers
which can be used to study populations at
risk and to verify an increased incidence of
adverse reproductive outcomes in exposed
individuals. In general, these investigations
provide biologic data that not only verify a
self-reported or dinically reported outcome
(e.g., an increased incidence of infertility,
menstrual dysfunction, or spontaneous
abortion), but also provide an indication of
the cause of the disorder (e.g., anovulation).
A second and related series of activities
requiring animal experimentation may be
needed to confirm a target of toxicity that is
indicated by the results of the field study,
and in some cases to verify that the putative
environmental hazard causes the types of
reproductive disorders that were observed
in the human populations. We will refer to
these activities as animal studies (Figure 1)
and they involve the efforts of reproductive
physiologists, toxicologists, and endocrinol-
ogists. For these experiments, an appropri-
ate animal model is selected, and for this
model, comparable biomarkers to those
being used in the human field studies are
developed and validated. Ideally, the animal
model is exposed to environmentally rele-
vant concentrations of a toxicant to which
humans are exposed and the biomarkers of
effect are analyzed to determine whether
the outcome of the human exposure can be
replicated in the model. If the toxicant has
not been identified, the animal studies may
utilize model compounds to identify tar-
get(s) of toxicity at the organ-system level
and to correlate these findings with the
results of the biomarker data.
The third area of in vitro studies
(Figure 1) follows from the whole-animal
studies when specific organ targets of toxic-
ity are identified. Experimental studies
utilizing cells and tissues from humans,
nonhuman primates, or other animal mod-
els can be designed to investigate the mech-
anism of toxic action at the biochemical
and molecular levels. Such experiments are
carried out by biochemists, toxicologists,
and molecular biologists. The results of
these studies allow predictions to be made
about the toxicity to reproductive tract
cells of related classes of chemical com-
pounds. Information obtained at each step
in these three cycles of investigation is
relevant to the overall objective of confirm-
ing that a putative toxicant is responsible for
the adverse effects that are revealed by the
reproductive biomarkers. The interdiscipli-
nary research that is portrayed in the three
cycles of activity requires close and continu-
ing interaction between the investigators.
Although many of the activities in one area
are dependent on information obtained in
other areas, the overall organization of the
program allows for simultaneous progress at
all levels of the investigation.
Human Studies
The stimulus for concerted research activity
in human reproductive toxicology is the
identification of exposed individuals with
impaired reproductive functions. In the case
of females, clinically apparent reproductive
diseases indude sterility, infertility (delay to
conception), spontaneous abortion, and
menstrual dysfunction. The instruments
that are used to identify these adverse repro-
ductive outcomes include menstrual cal-
endars and daily diaries (4,5) as well as
measurements of urinary biomarkers (6,7).
These biomarkers are metabolites of repro-
ductive hormones. Under field conditions,
multiple biomarkers may be needed for
detection of complex reproductive outcomes
such as pregnancy loss (6,8).
Clinical expertise is essential for under-
standing the reproductive diseases that are
suspected to have an environmental cause,
and for selecting the endocrine parameters
that can be used to identify these diseases. In
general, female reproductive function is
described not by absolute levels of hor-
mones, but rather by the patterns of hor-
mone fluctuation throughout the menstrual
cycle and during pregnancy. It is important
to understand the relationships between the
patterns of circulating hormones and the
patterns of hormone metabolite excretion in
urine. During the development of assays for
urinary hormone metabolites, consideration
must be given to the practicality of assay sys-
tems if they are to be cost-effective in large-
scale, population-based studies. Efficiency
and economy are as important as reliability
and accuracy in situations where tens of
thousands of samples must be analyzed.
Enzyme-based, microtiterplate-formatted
assays provide one method of reducing the
costs of both labor and materials. Such
assays have been developed in our laboratory
for the urinary metabolites of estradiol (E2)
and progesterone (Po) (9), luteinizing hor-
mone (LH) (10), follicle-stimulating hor-
mone (FSH) (11), and human chorionic
gonadotropin (hCG) (12).
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The process of validating assays for
biomarkers of adverse reproductive out-
comes includes laboratory exercises, as well
as observational studies of human subjects
in either a clinic or field setting. Initial lab-
oratory studies involve the addition of pure
standards to biologic fluids (usually urine
samples) and characterization of the assay
in terms of sensitivity, specificity, reliabil-
ity, and repeatability (11). Ideally, assays
for reproductive biomarkers are validated
using biologic samples collected in popula-
tion-based studies, but such samples are
frequently not available, and as mentioned
above, multiple sequential samples rather
than single samples are usually required to
assess reproductive functions. Therefore,
most validations of reproductive bio-
markers are carried out using samples from
clinic patients with the reproductive disor-
der that will be investigated in subsequent
field studies.
Biologic samples that are obtained in
field studies must be easily collected, han-
dled, and stored; this consideration is an
important aspect of biomarker assay devel-
opment and validation. Self-collected urine
samples have been used in most studies
that have investigated the adverse effects of
environmental hazards on reproduction.
Although this approach has been shown to
be feasible in a field setting, new methods
are currently being developed for collecting
urine on filter paper to create a dry sample
for easier storage and shipping (13).
Because urinary hormone metabolites are
not commonly measured by clinicians dur-
ing evaluation of abnormal reproductive
function, there is relatively little informa-
tion in the literature on the urinary hor-
mone profiles that are characteristic of
various reproductive disorders. Therefore,
clinical studies in normal women that
compare hormone concentrations in blood
and the corresponding concentrations of
urinary hormone metabolites are a neces-
sary first step in the validation process.
Such comparative studies have been pub-
lished by our laboratory on the profiles of
E2 and Po (9), LH (10), and FSH (8,11).
After laboratory and clinical/field valida-
tions, biomarker assays should be pilot
tested in a small field study to demonstrate
the adverse effect of a specific exposure. In
the pilot studies the biomarkers should be
compared to gold standards such as physical
examination, serum hormones, and clinical
assessments, and they should be character-
ized in terms of ability to detect the adverse
effect (sensitivity) and ability to discrimi-
nate between abnormal and normal subjects
(specificity). This phase of assay develop-
ment should also be used to streamline and
simplify the biomarker assay and the analy-
sis of assay results. If possible, computer
algorithms for interpretation of biomarker
data should be developed so that large data
sets can be managed with a minimum of
manipulation. An example of this kind of
simplification of methods is the algorithm
for detecting abnormal ovarian function
using a single biomarker assay for Po
metabolites (14). The algorithm was shown
to have a sensitivity of 75% and a speci-
ficity of 89.5% for identifying anovulatory
cycles in comparison with a serum Po "gold
standard." The method was applied in a
population-based study of 403 healthy
women recruited from a health care plan,
and 4.9% of these women experienced
anovulatory episodes (7).
Some endocrine patterns, such as those
associated with early pregnancy loss [also
known as early fetal loss (EFL)], are so com-
plex that multiple biomarkers must be
employed and individual assessments of
cycle-specific data are required to identify
adverse outcomes. We initially believed that
EFL could be identified as an outcome in
population-based studies if only hCG was
measured. However, clinical studies in
which circulating levels of hCG were mea-
sured on a daily basis suggested that false
negative results would be obtained if only
hCG is measured, as some cases of EFL may
not produce detectable levels of hCG in
urine (15). False positive detection of EFL
was demonstrated in population-based field
studies as a result of the presence ofhCG in
the urine of nonpregnant women (6). In an
effort to minimize both false positive and
false negative results, we investigated a num-
ber of ovarian hormones and how their
secretion patterns were changed in response
to circulating hCG. Changes in some of
these hormones such as relaxin (16) and
ovarian androgens (17) could be measured
in blood but were not suitable as urinary
biomarkers. We had previously developed
urinary assays for the metabolites of E2 and
Po (9), and demonstrated that the produc-
tion of these steroids is accelerated by hCG
(18). Together with hCG, these biomarkers
were measured in a large prospective study
of EFL involving analysis of approximately
70,000 daily urine samples collected in
more than 2500 menstrual cycles from 448
women employed in the semiconductor
industry (6). When hCG was present in an
ovulatory cycle and during the time when
implantation could take place, the cycle
classified as having EFL. Surprisingly, only
21 of the 38 cycles confirmed to be positive
for heterodimeric hCG met these criteria
(6). Altogether, five separate assays for four
different reproductive biomarkers were
required in order to fully interpret the
urinary hormone data.
Application of recently developed assays
for pituitary gonadotropins is likely to
reduce the number of biomarkers needed to
detect EFL. The assay that we previously
developed for urinary Po metabolites (9)
can be used to recognize the luteal phase of
the cycle, and identification of the midcycle
surge of FSH can be used to determine the
approximate day of ovulation (8), and thus
an implantation window in which hCG
excretion is likely to be a result of pregnancy
(6). An algorithm has been developed for
detection of pregnancy using only the uri-
nary FSH biomarker. The FSH algorithm
identified conceptive cycles with a sensitivity
of 88.9% and a specificity of 89.3%, com-
pared to the serum hCG gold standard, and
all six cases of EFL that were evaluated were
detected by the FSH algorithm (8).
To determine whether toxicity to the
mother or conceptus is responsible for EFL,
we have studied the biologic and biochemi-
cal characteristics of hCG as biomarkers of
embryonic well-being. The primary tool in
these investigations is a luminescence
LH/hCG bioassay based on the clonal
human fetal kidney cell line 293 which is
permanently transfected with human
LH/hCG receptor cDNA and a luciferase
reporter gene driven by a cAMP-dependent
promoter (19). First, we developed a radio-
receptor assay utilizing the membranes
from this transfected cell line which express
recombinant human LH/hCG receptors
(19). Next, we used the bioassay, the
radioreceptor assay, and two different
immunoassays for hCG to characterize cir-
culating hCG in the periimplantation
period of normal and failing pregnancies
(20). We found that a steep rise of bioac-
tive hCG is a consistent feature of the peri-
implantation period of normal pregnancies.
On the other hand, most failing pregnan-
cies produced hCG with lower biological
activity than the hCG of normal pregnan-
cies (20). The results of culture studies with
human trophoblast cells suggest that the
lower bioactive/immunoreactive (B:I) hCG
ratios observed in failing pregnancies are
related to reduced or impaired trophoblast
differentiation (21). Because the B:I hCG
ratio appears to identify pregnancies with
normal implantation, it may be possible in
future epidemiologic studies to evaluate
separately this subset of normal pregnancies
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for evidence of abortion resulting from
subsequent environmental exposures.
Animal Studies
Animal studies are an essential element in
the process of reproductive biomarker devel-
opment, because all human studies are, by
ethical necessity, observational rather than
experimental. Therefore, all investigations
that aim to identify the toxicant, its target of
toxicity, and its mechanism of action must
be carried out using animal models. Such
activities are particularly appropriate after
the identification of toxicants with putative
effects on human reproduction. In the case
of reproduction, the choice of models is lim-
ited because of species specificity in most of
the reproductive processes. Unique primate
characteristics involving gamete transport,
implantation, hormonal rescue of the corpus
luteum, and spontaneous sloughing of the
endometrium (menstruation) necessitate the
use of a nonhuman primate model for these
investigations, and most studies have been
carried out with the laboratory macaque.
Limitation of animal numbers and the
expense of animal care and resources dictate
that such studies be thoroughly justified and
carefully planned to provide the necessary
information with the smallest number of
animals possible.
Regardless of the similarity between the
physiology of the primate model and the
human, whenever possible, the same bio-
markers that are used for human surveil-
lance should be developed for the primate
and validated in that species using the same
approach as in the human studies. Initially,
we established serum assays for macaque E2
and Po and for their urinary metabolites
(22). A urinary assay for the metabolites of
FSH (11) also has been validated for assess-
ing macaque pituitary function (23).
Previously, there was no reliable assay for
monkey chorionic gonadotropin (mCG)
and this assay also has been developed (24).
These assay systems have enabled us to
design studies in which the biomarkers that
are used to monitor human reproductive
functions in epidemiologic studies are also
employed to assess the results of experimen-
tal manipulations in the monkey model.
We have used the monkey model for
investigating primary ovarian failure as a
result of follicle depletion (25,26). Such a
model is essential as an adjunct to ablation
experiments or experiments with toxicants in
which ovarian function is compromised.
This model has permitted us to characterize
the escape of pituitary gonadotropins as a
consequence of release from ovarian negative
feedback in the monkey, and to compare
that phenomenon with perimenopausal
events in the human. The data from the
monkeys 22 years of age and older reveal
oligomenorrhea, low ovarian steroids, and
elevated FSH excretion (26), as predicted
from our characterization of perimenopausal
women (27). These data validate the
approach that we use to determine central
versus ovarian targets of toxicity.
Our ongoing studies of dioxin toxicity
in the laboratory macaque are an example of
how animal studies use the principles and
technologies of the human biomarker devel-
opment and can lead to the identification of
targets of toxicity and mechanisms of
action. Macaques which had been treated
with 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) were evaluated for ovarian func-
tion more than a year after treatment (28).
Animals that received higher doses of
TCDD exhibited oligomenorrhea, low
ovarian steroid levels, and elevated levels of
FSH excretion. In contrast, the animals that
received lower doses ofTCDD had normal
menstrual calendars and normal steroid pro-
files with low-normal FSH excretion (28).
These data suggest that the ovary is a target
for TCDD toxicity, an outcome that was
also observed when TCDD was given to
macaques during early pregnancy.
Prior to initiation of the whole-animal
studies of the effects of toxicants on preg-
nancy, we developed methods for detection
of early pregnancy using endocrine assays
for mCG (24) and ultrasound evaluation
(29), both ofwhich are capable of detecting
pregnancy by gestation day (GD) 12 (29).
To characterize the biomarkers associated
with EFL in the macaque, luteectomy (sur-
gical removal of the active corpus luteum)
was performed to eliminate ovarian support
of the pregnancy, or methotrexate was
instilled into the uterine cavity via ultra-
sound guidance to simulate early demise of
the conceptus (30). The results of these
studies not only confirmed the choice of
animal model by comparison to the urinary
profiles in human spontaneous abortions,
but also provided critical information for
demonstrating that biomarkers could be
used to identify effects of toxicants on
specific target organs.
The in vivo experiments that included
TCDD treatment of pregnant animals fol-
lowed basic pharmacodynamic and phar-
macokinetics studies in nonpregnant
animals and confirmed the adverse effects
ofTCDD on early pregnancy in the pri-
mate model. The experiments also demon-
strated how well the biomarkers detected
EFL and, by comparison to the biomarker
profiles following surgical- and chemical-
induced EFL, they revealed the targets of
dioxin toxicity. Females were administered
single doses of 1, 2, and 4 pg/kg TCDD
(n= 4 per dose group) by nasogastric intu-
bation on gestational day (GD) 12 of preg-
nancy. Hormones were monitored in serum
(E2, Po, mCG) and their metabolites were
measured in urine to assess ovarian and pla-
cental endocrine status (31). Early preg-
nancy loss occurred between GDs 22 and
32 in 10 of the 12 animals treated with
TCDD. None of the seven control animals
treated with vehicle had a pregnancy loss.
The primary endocrine alteration associated
with embryo loss was lowered steroid levels
(Po and E2) indicative of a direct effect of
TCDD on ovarian function. Although the
urinary metabolites of E2 and Po did not
have the same profile as the serum biomark-
ers, evaluation of the urinary biomarkers
led to similar conclusions regarding the
time and site of toxic action (31). As these
urinary metabolites are the same biomark-
ers that are measured in population-based
studies, this demonstration of their applica-
tion in the nonhuman primate model will
enable future comparisons to be made
between human biomarker data and lab-
oratory animal experiments in which the
putative human reproductive toxicant is
studied. In addition, the results of animal
studies demonstrating organ targets of toxi-
city shift the focus of investigations to in
vitro systems in which mechanistic studies
can be performed.
In Vitro Studies
Following establishment of dose- and
time-response relationships for toxicants in
vivo and identification of the target organ(s)
and/or cell(s), in vitro studies of the mecha-
nisms of toxicity at the biochemical and
molecular levels become meaningful
(Figure 1). The design of these studies is
guided by results obtained in the whole-
animal experiments, and in particular the
tissues and cell types that were identified as
targets of the toxicant. Some in vitro studies
can be carried out with tissues or cells from
the primate model (32); in other studies,
experiments with human cells and tissues
are appropriate (33). When appropriate,
the mechanistic studies should focus on
effects of the toxicant on hormone produc-
tion and/or hormone action in reproductive
tract cells. A continued focus on the pro-
duction and action of the reproductive hor-
mones ensures continuity and relevance
between all areas of the integrated research
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program. Specifically, the population-based
human studies in which these hormones
serve as biomarkers are linked to the animal
studies in which the fluctuations in these
hormones are shown to cause disease. These
activities in turn are linked to the in vitro
studies, in which the mechanisms of toxic
action are demonstrated with hormone-
producing and/or hormone-responsive cells.
Once the in vitro studies using animal tis-
sues have demonstrated the adverse effects
of the toxicant, then the same types of
human tissues can be studied in experi-
ments of similar design. On the basis of the
knowledge gained from these human in
vitro experiments, strong inference can be
made that the putative toxicant was respon-
sible for the reproductive disorders observed
in the exposed human populations.
The identification of ovarian cells as a
primary target of toxicity in whole-animal
studies of TCDD toxicity (31) led to
investigations of ovarian cells after in vitro
exposure to TCDD (34,35). These studies
with human luteinized granulosa cells
demonstrated an effect of TCDD on the
production of E2 (34) as well as Po (35).
Such experiments were useful in docu-
menting that the adverse effects of in vivo
exposures can be detected and studied in
vitro. The in vivo exposures with in vitro
follow-up also allow us to demonstrate
that TCDD was not acting indirectly or
through activation prior to targeting ovar-
ian cells. Following the demonstration of a
direct effect ofTCDD on ovarian cells, a
series of in vitro studies was designed,
focusing first on time course and dose-
response characteristics (35). We were able
to use human and monkey cells simultane-
ously and demonstrate a negative effect of
TCDD on steroid production in both cell
types (32,34,35). In this specific example,
the results of the in vitro studies demon-
strated that TCDD acts through the Ah
receptor in both human and monkey
granulosa cells (32,35).
Related research with rodent models
provided mechanistic insights that were
applied directly to the design of experiments
with TCDD and primate reproductive
tract cells. The results of initial experi-
ments with guinea pig and monkey adipose
tissues demonstrated that one mechanism
of TCDD toxicity involved phosphoryla-
tion cascades that. modulate AP- 1 and
other transcription factors (36). Subsequent
studies with rats have shown that these
effects can be modulated by the actions of
sex steroids (37). Our experiments with
human granulosa cells suggest that in
Human
studies
Animal
studies
Verification of adverse
effect(s) in human
populations
In vitro\/l studies
Figure 2. A composite of the individual activities from all three cycles are shown as they occur in a single
integrated study. Although the sequence of progress may vary with specific circumstances and individual activities
may be added or deleted, the overall objective of the plan is to develop methods and knowledge that enable an
epidemiologic study to be conducted to verify or deny that an adverse reproductive health effect has resulted from
exposure to a specific environmental hazard.
reproductive tract cells, as in adipose cells,
one mechanism ofTCDD toxicity involves
interference with cytosolic phosphorylation
cascades (34).
Integration
In the context of an integrated research
program (Figure 2), this study design
enhances the prospect of identifying and
verifying hazards to reproductive health
that affect human populations. Depending
on the technology and information that is
already available, many of the steps and
even some phases of the study design
would not be necessary. The key element is
the focus on reproductive hormones. The
logic for using the metabolites of these hor-
mones as reproductive biomarkers is
derived from clinical experience in diag-
nosing infertility and is supported by
animal experiments in which perturbations
of these hormones result from toxicant
exposures. Finally, the circle is closed by
demonstration at the cellular and molecu-
lar level of the mechanisms by which toxi-
cants affect hormone production and
hormone action.
Summary and Conclusion
An integrated research program is
described that is designed to investigate the
adverse effects of environmental hazards on
female reproductive health. Although this
program has been designed to investigate
hazards to reproduction, the same general
approach could be used to study any
adverse health effect or environmental fac-
tor. The logical progression of steps ensures
that appropriate tools for future health sur-
veillance will be available, increases the
likelihood that toxicants will be identified,
and provides an efficient and effective
approach to investigate the mechanisms of
toxicity. The program requires collabora-
tion between investigators with diverse
backgrounds and skills as well as continu-
ous transfer of information and technology
between them. Such an approach is appro-
priate for multidisciplinary centers such as
the Superfund Basic Research Centers.
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